|
��չ����
|
|
| ������Ϣ | |
 |
Supporting info |
|
PDFȫ�� |
|
[HTMLȫ��] |
|
����� |
| �����뷴�� | |
|
�������ù����� |
|
���� |
|
Email Alert |
|
���·��� |
|
���������Ϣ |
| ���Ĺؼ���������� | |
|
Ƥ������ |
|
����ø�����-2 |
|
���������� |
|
ҩ������ |
| ��������������� | |
|
���� |
|
������ |
|
��ȫ�� |
| PubMed | |
|
Article by Zhu,y |
|
Article by Hu,J.H |
|
Article by Zhu,Q.G |
Ƥ�������������ƺ�ҩ�����Ƶ��°е�
����1,������2,��ȫ��3
1. �ڶ���ҽ��ѧ��������ҽԺ
2. �Ϻ�����ҽԺҩѧ��
3. �Ϻ��ڶ���ҽ��ѧ��һ����ҽԺҩѧ��
null
Pathogenesis and new therapy targets of pruritus
The neurophysiological basis for pruritus has remained unclear for decades. The discovery of itch-mediating nerve fibers considerably has expanded knowledge on the pathogenesis of pruritus. Antihistamines are used in the treatment of pruritus most commonly, but their efficacy in chronic pruritus is unsatisfactory. Many endogenous chemicals are locally pruritogenic when injected into the skin, including growth factors, neuropeptides, eicosanoids and cytokines. Proteinase activated receptor-2 ��PAR-2�� and transient receptor potential vanilloid ��TRPV-1�� have turned into new targets of medication for pruritus.
������Ȼ��ѧ����������Ŀ